Recent advances in non-competitive mGlu5 receptor antogonists and their potential therapeutic applications

Current Topics in Medicinal Chemistry

Volumn 5, Issue 9, 2005, Pages 897-911

  Slassi, Abdelmalik ^a   Isaac, Methvin ^a   Edwards, Louise ^a   Minidis, Alexander ^b   Wensbo, David ^b   Mattsson, Jan ^b   Nilsson, Karolina ^b   Raboisson, Patrick ^b   McLeod, Donald ^c   Stormann, Thomas M ^c   Hammerland, Lance G ^c   Johnson, Edwin ^d  

^a NPS Pharmaceuticals Inc   (Canada)

^b ASTRAZENECA R AND D   (Sweden)

^c NPS Pharmaceutical Inc   (United States)

^d AstraZenea LP   (United States)

Author keywords

Antagonist; Glutamate; mGlu5 receptor

Indexed keywords

2 [4 [2 (2 CHLOROPYRIDIN 4 YL)ETHYNYL] 2 METHYL IMIDAZOL 1 YL] 6 TRIFLUOROMETHYLPYRIDINE; 2 CYCLOPROPYL 6 [2 METHYL 4 (2 METHYL PYRIDIN 4 YL ETHYNYL)IMIDAZOL 1 YL]PYRIDINE; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3,5 DIHYDROXYPHENYLGLYCINE; 4 AMINOBUTYRIC ACID RECEPTOR; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; [4 (1,3 BENZOXAZOL 2 YL) 2 CHLOROPHENYL]ACETONITRILE; CALCIUM; COCAINE; DIPYRIDIN 3 YLISOXAZOLO[4,5 C]PYRIDIN 4(5H) ONE; DOPAMINE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; HALOPERIDOL; IMIDAZOLE DERIVATIVE; INSULIN; LEPTIN; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXADIAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANTINOCICEPTION; ANXIETY DISORDER; BINDING AFFINITY; BINDING ASSAY; CHRONIC PAIN; CLINICAL FEATURE; COCAINE DEPENDENCE; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FRAGILE X SYNDROME; GASTROESOPHAGEAL REFLUX; HALLUCINATION; HUMAN; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; LOCOMOTION; MUSCLE RIGIDITY; NERVE CELL STIMULATION; NEUROTOXICITY; NOCICEPTION; NONHUMAN; OBESITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYNAPTIC TRANSMISSION; TOBACCO DEPENDENCE; TRANQUILIZING ACTIVITY;

ANIMALS; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 24644454231     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054750236     Document Type: Review

References (118)

1. Lujan, R.; Nusser, Z.; Roberts, J.D.; Shigemoto, R.; Somogyi, P.; Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur. J. Neurosci. 1996, 8, 1488-500.
2. Romano, C.; Sesma, M.A.; McDonald, C.T.; O'Malley, K.; Van den Pol, A.N.; Olney, J.W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 1995, 355(3), 455-69.
3. Shigemoto, R.; Nomura, S.; Ohishi, H.; Sugihara, H.; Nakanishi, S.; Mizuno, N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 1993, 163, 53-7.
4. Romano, C.; van den Pol, A.N; O'Malley, K.L.; Enhanced early developmental expression of the metabotropic glutamate receptor mGluR5 in rat brain, protein, mRNA splice variants, and regional distribution. J. Comp. Neurol. 1996, 367, 403-12.
5. Gasparini, F.; Kuhn, R.; Pin, J.P. Allosteric modulators of group I metabotropic glutamate receptors, novel subtype-selective ligands and therapeutic perspectives. Curr. Opin. Pharmacol. 2002, 2(1), 43-9.
6. Spooren, W.P.; Vassout, A.; Neijt, H.C.; Kuhn, R.; Gasparini, F.; Roux, S.; Porsolt, R.D.; Gentsch, C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl) pyridine in rodents. J. Pharmacol. Exp. Ther. 2000, 295(3), 1267-1275.
7. Brodkin J.; Busse C.; Sukoff S.J.; Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 2002, 73(2), 359-366.
8. Schulz B.; Fendt M.; Gasparini F.; Lingenhohl K.; Kuhn R.; Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 2001, 41(1), 1-7.
9. Spooren, W.P.; Schoeffter, P.; Gasparini, F.; Kuhn, R.; Gentsch, C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol. 2002, 435(2-3), 161-170.
10. Ballard, T.M.; Woolley, M.L.; Prinssen, E.; Huwyler, J.; Porter, R.; Spooren, W. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition, a comparison. Psychopharmacology 2005, 179(1), 218-229.
11. Varty, G.B.; Grilli, M.; Forlani, A.; Fredduzzi, S.; Grzelak, M.E.; Guthrie, D.H.; Hodgson, R.A.; Lu, S.X; Nicolussi, E.; Pond, A.J.; Parker, E.M.; Hunter, J.C.; Higgins, G.A.; Reggiani, A.; Bertorelli, R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents, a comparison of efficacy and side-effect profiles. Psychopharmacology 2005, 179(1), 207-217.
12. Walker, K.; Bowes, M.; Panesar, M.; Davis, A.; Gentry, C.; Kesingland, A.; Gasparini, F.; Spooren, W.; Stoehr, N.; Pagano, A.; Flor, P.J.; Vranesic, I.; Lingenhoehl, K.; Johnson, E.C.; Varney, M.; Urban, L.; Kuhn, R. Metabotropic glutamate receptor subtype5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology 2001, 40(1), 1-9.
13. Zhu, C.Z.; Wilson, S.G.; Mikusa, J.P.; Wismer, C.T.; Gauvin, D.M.; Lynch, J.J. 3rd, Wade, C.L.; Decker, M.W.; Honore, P. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J. Pharmacol. 2004, 506(2), 107-118.
14. Hudson, L.J.; Bevan, S.; McNair, K.; Gentry, C.; Fox, A.; Kuhn, R.; Winter, J. Metabotropic glutamate receptor 5 upregulation in A-fibers after spinal nerve injury, 2-methyl-6-(phenylethynl-pyridine (MPEP) reverses the induced thermal hyperalgesia. J. Neurosci. 2002, 22(7), 2660-68.
15. Urban, M.O.; Hama, A.T.; Bradbury, M.; Anderson, J.; Varney, M.A.; Bristow, L. Role of metabotropic glutamate receptor subtype 5 (mGluR5) in the maintenance of cold hypersensitivity following a peripheral mononeuropathy in the rat. Neuropharmacol. 2003, 44, 983-93.
16. Spooren, W.P.; Gasparini, F.; Bergmann, R.; Kuhn, R. Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur. J. Pharmacol. 2000, 406(3), 403-410.
17. Breysse, N.; Baunez, C.; Spooren, W.; Gasparini, F.; Amalric, M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 2002, 22(13), 5669-5678.
18. Ossowska, K.; Konieczny, J.; Wolfarth, S.; Wieronska, J.; Pilc, A. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology 2001, 4(4), 413-420.
19. Turle-Lorenzo, N.; Breysse, N.; Baunez, C.; Amalric, M. Functional interaction between mGlu5 and NMDA receptors in a rat model of Parkinson's disease. Psychopharmacology 2005, 179 (1), 117-127.
20. Ossowska, K.; Konieczny, J.; Wolfarth, S.; Pilc, A. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 2005, in press.
21. Chapman, A.G.; Nanan, K.; Williams, M.; Meldrum, B.S. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology 2000, 39(9), 1567-1574.
22. Moldrich, R.X; Chapman, A.G.; De Sarro, G.; Meldrum, B.S. Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur. J. Pharmacol. 2003, 476(1-2), 3-16.
23. Mares, P.; Mikulecka A. MPEP, an antagonist of metabotropic glutamate receptors, exhibits anticonvulsant action in immature rats without a serious impairment of motor performance. Epilepsy Res. 2004, 60(1), 17-26.
24. O'Donnell, W.T.; Warren, S.T. A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 2002, 25, 315-338.
25. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends. Neurosci. 2004, 27(7), 370-377.
26. Chiamulera, C.; Epping-Jordan, M.P.; Zocchi, A.; Marcon, C.; Cottiny, C.; Tacconi, S.; Corsi, M.; Orzi, F.; Conquet, F. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 2001, 4(9), 873-874.
27. Tessari, M.; Pilla, M.; Andreoli, M.; Hutcheson, D.M.; Heidbreder, C.A. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur. J. Pharmacol. 2004, 499(1-2), 121-133.
28. Rasmussen, K.; Martin, H.; Berger, J.E.; Seager, M.A. The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats. Neuropharmacology 2005, 48(2), 173-180.
29. Backstrom, P.; Bachteler, D.; Koch, S.; Hyytia, P.; Spanagel, R. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology 2004, 29(5), 921-928.
30. Bradbury, M.J.; Campbell, U.; Giracello, D.; Chapman, D.; King, C.; Tehrani, L.; Cosford, N.D.; Anderson, J.; Varney, M.A.; Strack, A.M. Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. J. Pharmacol. Exp. Ther. 2005, 313(1), 395-402
31. Jensen, J.; Lehmann, A.; Hulander M.; Uvebrant, A.;, Carlsson, A.; Umaerus, M.; Nilsson, K.; Frisby, C.; Blackshaw, A.; Mattsson, J. The metabotropic glutamate receptor 5 inhibits transient lower esophageal sphincter relaxations in the dog. Abstracts from the Digestive Disease Week (DDW) Annual Meeting 2004, New Orleans, LA. Abstr. W1421
32. Frisby, C.; Mattsson, J.; Jensen, J.; Lehmann, A.; Dent, J.; Blackshaw, A. Involvement of Group-I metabotropic glutamate receptors in the mechanism of transient LES relaxation in the conscious ferret. Abstracts from the Digestive Disease Week (DDW) Annual Meeting 2004, New Orleans, LA. Abstr. 447.
33. Varney, M.A.; Cosford, N.D.; Jachec, C.; Rao, S.P.; Sacaan, A.; Lin, F.F.; Bleicher, L.; Santori, E.M.; Flor, P.J.; Allgeier, H.; Gasparini, F.; Kuhn, R.; Hess, S.D.; Velicelebi, G.; Johnson, E.C. SIB-1757 and SIB-1893, selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J Pharmacol. Exp. Ther. 1999, 290(1), 170-181
34. Gasparini, F.; Andres, H.; Flor, P.J.; Heinrich, M.; Inderbitzin, W.; Lingenhohl, K.; Muller, H.; Munk, V.C.; Omilusik, K.; Stierlin, C.; Stoehr, N.; Vranesic, I.; Kuhn, R. [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg. Med. Chem. Lett. 2002, 12(3), 407-409.
35. 3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy, potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg. Med. Chem. Lett. 2003, 13(3), 351-354.
36. Roppe, J.R.; Wang, B.; Huang, D.; Tehrani, L.; Kamenecka, T.; Schweiger, E.J.; Anderson, J.J.; Brodkin, J.; Jiang, X.; Cramer, M.; Chung, J.; Reyes-Manalo, G.; Munoz, B.; Cosford, N.D. 5-[(2-Methyl-1,3-thiazol-4-yl)ethyny]-2,3′-bipyridine, a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity. Bioorg. Med. Chem. Lett. 2004, 14(15), 3993-3996.
37. Alagille, D.; Baldwin, R.M.; Roth, B.L.; Wroblewski, J.T.; Grajkowska, E.; Tamagnan, G.D. Synthesis and receptor assay of aromatic-ethynyl-aromatic derivatives with potent mGluR5 antagonist activity. Bioorg. Med. Chem. 2005, 13(1), 197-209.
38. Bolea, C.; Mutel, V.; Rocher, J.P.; Bessis, A.S.; Le Poul, E. New aminopyridine derivatives are mGluR5 antagonists - useful for treating CNS disorders. WO-2004078728, Mar. 16, 2004.
39. Buettelmann, B.; Ceccarelli, S.M.; Jaeschke, G.; Kolczewski, S.; Porter, R.H.P.; Vieira, E. New imidazole compounds are mGluR5 antagonists - useful for the treatment of psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficit and pain. US-20040248888 June 05, 2003.
40. Buettelmann, B.; Ceccarelli, S.M.; Jaeschke, G.; Kolczewski, S.; Porter, R.H.P.; Vieira, E. New 4-(imidazol-4-yl-ethynyl)-2-alkyl-pyridine derivatives are mGluR5 antagonists - useful for treating anxiety. WO-2004080998, Mar. 10, 2003.
41. Van Wagenen, B.; Stormann, T.; Moe S.T.; Sheehan, S.M.; McLeod, D.; Smith, D.; Isaac, M.; Slassi, A. Heteropolycyclic compounds and their use as metabotrophic glutamate receptor antagonists WO-00112627, Feb. 22, 2001.
42. Roppe, J.; Smith, N.D.; Huang, D.; Tehrani, L.; Wang, B.; Anderson, J.; Brodkin, J.; Chung, J.; Jiang, X.; King, C.; Munoz, B.; Varney, M.A.; Prasit, P.; Cosford, N.D. Discovery of novel heteroarylazoles that are metabotropic, glutamate subtype 5 receptor antagonists with anxiolytic activity. J. Med. Chem. 2004, 47(19), 4645-4648.
43. Wang, B.; Vernier, J.M.; Rao, S.; Chung, J.; Anderson, J.J.; Brodkin, J.D.; Jiang, X.; Gardner, M.F.; Yang, X.; Munoz, B. Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg. Med. Chem. 2004, 12(1), 17-21.
44. Anderson J.J.; Bradbury M.J.; Giracello D.R.; Chapman D.F.; Holtz G.; Roppe J.; King C.; Cosford N.D.; Varney M.A. In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur. J. Pharmacol. 2003, 473(1), 35-40.
45. Brodkin, J.; Busse, C.; Sukoff, S.J.; Varney, M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 2002, 73(2), 359-366.
46. Bonnefous, C.; Vernier, J.M.; Hutchinson, J.H.; Chung, J.; Reyes-Manalo, G.; Kamenecka, T. Dipyridyl amides, potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15(4), 1197-1200.
47. Mutel, V.; Peters, J-U.; Wichmann, J. Imidazo[1,2-a]pyridine derivatives as mGluR5 antagonists useful for treating neurological disorders. WO02092086, Mar. 21, 2002.
48. Nakamura, M.; Kurihara, H.; Ohkubo, M.; Tsukamoto, N. Novel isoxazolopyridone derivatives and use thereof. PCT Patent appl. WO02102807, XXXXX, 2002.
49. Gharagozloo, P.; Islam, K.; Kyle, D.J.; Sun, Q.; Tafesse, L.; Whitehead, J.W.F.; Yang, J.; Zhou, X. Novel 1-(pyridin-2-yl) piperazine derivatives as mGluR5 antagonists useful for treating pain, anxiety, depression and other disorders. WO-03093236, Nov 13, 2003.
50. Gharagozloo, P. New alkyne derivatives are mGluR5 and/or mGluR1 inhibitors - Useful in the treatment of pain and neurological and psychiatric disorders. WO-05035500, Apr, 20035.
51. Hamill, T.G.; Krause, S.; Ryan, C.; Bonnefous, C.; Govek, S.; Seiders, T.J.; Cosford, N.D.; Roppe, J.; Kamenecka, T.; Patel, S.; Gibson, R.E.; Sanabria, S.; Riffel, K.; Eng, W.; King, C.; Yang, X.; Green, M.D.; O'malley, S.S.; Hargreaves, R.; Burns, H.D. Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers. Synapse, 2005, 56(4), 205-216.
52. Le Doux, J.E.; Iwata, J.; Cicchetti, P.; Reis, D.J. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J. Neurosci. 1997, 8, 2517-29.
53. Davis, M. Neurobiology of fear response, the role of the amygdala. J. Neuropsychiatry Clin. Neurosci. 1997, 9, 382-402.
54. Fendt, M.; Fanselow, M.S. The neuroanatomical and neurochemical basis of conditioned fear. Neurosci. Biobehav. Rev. 1999, 23, 743-60.
55. Goosens, K.A.; Maren, S. Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloid nuclei in rats. Learning Memory 2001, 8, 148-55.
56. Rogan, M.T.; Staubli, U.V.; LeDoux, J.E. Fear conditioning induces associative long-term potentiation in the amygdala. Nature 1997, 390, 604-7.
57. McKernan, M.G.; Shinnick-Gallagher, P. Fear conditioning induces a lasting potentiation of synaptic current in vivo. Nature. 1997, 390, 607-11.
58. Bauer, E.P.; LeDoux, J.E.; Nader, K. Fear conditioning and LTP in the lateral amygdala are sensitive to the same stimulus contingencies. Nature Neurosci. 2001, 4, 687-8.
59. Lu, Y.M.; Jia, Z.; Janus, c.; Henderson, J.T.; Gerlai, R.; Wojtowicz, J.M.; Roder, J.C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 1997, 17, 5196-205.
60. Rodrigues, S.M.; Bauer, E.P.; Farb, C.R.; Schafe, G.E.; LeDoux, J.E. The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J. Neurosci. 2002, 22, 5219-29.
61. Fendt, M.; Schmid, S. Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur. J. Neurosci. 2002, 15, 1535-41.
62. Gasparini, F.; Lingenhohl, K.; Stoehr, N.; Flor, P.J.; Heinrich, M.; Vranesic, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Urwyler, S.; Varney, M.A.; Johnson, E.C.; Hess, S.D.; Rao, S.P.; Sacaan, A.I.; Santori, E.M.; Velicelebi, G.; Kuhn, R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38(10), 1493-1503.
63. Pilc, A.; Klodzinska, A.; Branski, P.; Nowak, G.; Palucha, A.; Szewczyk, B.; Tatarczynska, E.; Chojnacka-Wojcik, E.; Wieronska, J.M. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 2002, 43 181-187.
64. Steckler, T.; Lavreysen, H.; Olivera, A.M.; Aerts, N.; Van Craenendonck, H.; Prickaerts, J.; Megens, A.; Lesage, A.S. Effects of mGlu1 receptor blockade on anxiety-related behavior in the rat lick suppression test. Psychopharmacol. (Berl). 2005 Dec 4;
65. Cosford, N.D.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N.D.; Anderson, J.; Bristow, L.; Brodkin, J.; Jiang, X.; McDonald, I.; Rao, S.; Washburn, M.; Varney, M.A. 3-[(2-Methyl-1,3-thiazol-4-yl) ethynyl]-pyridine, a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 2003, 46(2), 204-6.
66. Busse, C.S.; Brodkin, J.; Tattersall, D.; Anderson, J.J.; Warren, N.; Tehrani, L.; Bristow, L.J.; Varney, M.A.; Cosford, N.D. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004, 29, 1971-79.
67. Riedel, G.; Casabona, G.; Platt, B.; Macphail, E.M.; Nicoletti, F. Fear conditioning-induced time- and subregion-specific increase in expression of mGlu5 receptor protein in rat hippocampus. Neuropharmacology 2000, 39, 1943-1951.
68. Klodzinska, A.; Tatarczynska, E.; Chojnacka-Wojcik E, Nowak G, Cosford ND, Pilc A. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology 2004, 47(7), 1115.
69. Wieronska, J.M.; Smialowska, M.; Branski, P.; Gasparini, F.; Klodzinska, A.; Szewczyk, B.; Palucha, A.; Chojnacka-Wojcik, E.; Pilc, A. In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling. Neuropsychopharmacology 2004, 29(3), 514-21.
70. Fundytus, M.E. Glutamate receptors and nociception, implications for the drug treatment of pain. CNS Drugs 2001, 15(1), 29-58.
71. Chizh, B.A. Novel approaches to targeting glutamate receptors for the treatment of chronic pain, review article. Amino Acids 2002, 23(1-3), 169-76.
72. Varney, M.A.; Gereau, R.W. IV. Metabotropic glutamate receptor involvement in models of acute and persistent pain, prospects for the development of novel analgesics. Curr. Drug Targets 2002, 1, 283-96.
73. Neugebauer, V. Metabotropic glutamate receptors - important modulators of nociception and pain behavior. Pain 2002, 98, 1-8.
74. Walker, K.; Reeve, A.; Bowes, M.; Winter, J.; Wotherspoon, G.; Davis, A.; Schmid, P.; Gasparini, F.; Kuhn, R.; Urban, L. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology 2001, 40(1), 10-19.
75. Valerio, A.; Rizzonelli, P.; Paterlini, M.; Moretto, G.; Knopfel, T.; Kuhn, R.; Memo, M.; Spano, P. mGluR5 metabotropic glutamate receptor distribution in rat and human spinal cord, a developmental study. Neurosci. Res. 1997, 28(1), 49-57.
76. Bhave, G.; Karim, F.; Carlton, S.M.; Gereau, R.W. IV. Peripheral group I metabotropic glutatmate receptors modulate nociception in mice. Nat. Neurosci. 2001, 4(4), 417-23.
77. Vidnyanszky, Z.; Hamori, J.; Negyessy, L.; Ruegg, D.; Knopfel, T.; Kuhn, R.; Gorcs, T.J. Cellular and subcellular localization of the mGluR5a metabotropic glutamate receptor in rat spinal cord. Neuroreport 1994, 6(1), 209-13.
78. Valerio, A.; Rizzonelli, P.; Paterlini, M.; Moretto, G.; Knopfel, T.; Kuhn, R.; Memo, M.; Spano, P. Metabotropic glutamate receptor mRNA expression in rat spinal cord. Neuroreport 1997, 8(12), 2695-99.
79. Jia, H.; Rustioni, A.; Valtschanoff, J.G. Metabotropic glutamate receptors in superficial laminae of the rat dorsal horn. J. Comp. Neurol. 1999, 410(4), 627-42.
80. Azkue, J.J.; Knopfel, T.; Kuhn, R.; Mateos, J.M.; Grandes, P. Distribution of the metabotropic glutamate receptor subtype mGluR5 in rat midbrain periaqueductal grey and relationship with ascending spinofugal afterents. Neurosci, Lett. 1997, 228(1), 1-4.
81. Fisher, K.; Coderre, T.J. Comparison of nociceptive effects produced by intrathecal administration of mGluR agonists. Neuroreport 1996a, 7, 2743-47.
82. Fisher, K.; Coderre, T.J. Hyperalgesia and allodynia induced by intrathecal (RS)-dihydroxyphenylglycine in rats. Neuroreport 1998, 9, 1169-72.
83. Karim, F.; Wang, C.-C.; Gereau, R.W. IV. Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. J. Neurosci. 2001, 21(11), 3771-79.
84. Lorrain, D.S.; Correa, L.; Anderson, J.; Varney, M. Activation of spinal group I metabotropic glutamate receptors in rats evokes local glutamate release and spontaneous nociceptive behaviors, effects of 2-methyl-6-(phenylethynyl)-pyridine pretreatment. Neurosci. Lett. 2002, 327, 198-202.
85. Bordi, F.; Ugolini, A. Involvement of mGluR(5) on acute nociceptive transmission. Brain Res. 2000, 87(2), 223-33.
86. Binns, K.E.; Salt, T.E. Actions of the systemically active metabotropic glutamate antagonist MPEP on sensory responses of thalamic neurones. Neuropharmacology 2001, 40(5), 639-44.
87. Dogrul, A.; Ossipov, M.H.; Lai, J.; Malan, T.P. Jr.; Porreca, F. Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGLUR(5)) antagonist, in experimental neuropathic pain in rats. Neurosci. Lett. 2000, 292(2), 115-8.
88. Fisher, K.; Coderre, T.J. The contribution of metabotropic glutamate receptors (mGluRs) to formalin-induced nociception. Pain 1996b, 68(2-3), 255-63.
89. Fisher, K.; Lefebvre, C.; Coderre, T.J. Antinociceptive effects following intrathecal pretreatment with selective metabotropic glutamate receptor compounds in a rat model of neuropathic pain. Pharmacol. Biochem. Behav. 2002, 73, 411-18.
90. Hama, A.T. Acute activation of the spinal cord metabotropic glutamate subtype-5 receptor leads to cold hypersensitivity in the rat. Neuropharmacology 2003, 44, 423-30.
91. Sotgiu, M.L.; Bellomi, P.; Biella, G.E.M. The mGluR5 selective antagonist 6-methyl-2-(phenylethynyl)-pyridine reduces the spinal neuron pain-related activity in mononeuropathic rats. Neurosci. Lett. 2003, 342, 85-88.
92. de Novellis, V.; Siniscalco, D.; Galderisi, U.; Fuccio, C.; Nolano, M.; Santoro, L., Cascino, A.; Roth, K.A.; Rossi, F.; Maione, S. Blockade of glutamate mGlu5 receptors in a rat model of neuropathic pain prevents early over-expression of pro-apoptotic genes and morphological changes in dorsal horn lamina II. Neuropharmacology 2004, 46, 468-79.
93. DeLong, M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990, 13(7), 281-285.
94. Klockgether T, Turski L. Excitatory amino acids and the basal ganglia, implications for the therapy of Parkinson's disease. Trends Neurosci. 1989, 12(8), 285-286.
95. Chase, T.N.; Oh, J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 2000, S86-91.
96. Ossowska, K. The role of excitatory amino acids in experimental models of Parkinson's disease. J. Neural. Transm. (Park Dis. Dement Sect.) 1994, 8(1-2), 39-71.
97. Amalric, M.; Baunez, C.; Nieoullon, A. Does the blockade of excitatory amino acid transmission in the basal ganglia simply reverse reaction time deficits induced by dopamine inactivation? Behav. Pharmacol. 1995, 6(5 And 6), 508-519.
98. Rouse, S.T.; Marino, M.J.; Bradley, S.R.; Awad, H.; Wittmann, M.; Conn, P.J. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit, implications for treatment of Parkinson's disease and related disorders. Pharmacol. Ther. 2000, 88(3), 427-435.
99. Breysse, N.; Amalric, M.; Salin, P. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci. 2003, 23(23), 8302-9.
100. McGeehan, A.J.; Olive, M.F. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 2003, 47(3), 240-2.
101. van den Pol, A.N.; Romano, C.; Ghosh, P. Metabotropic glutamate receptor mGluR5 subcellular distribution and developmental expression in hypothalamus. J. Comp. Neurol. 1995, 362(1), 134-50.
102. Kerner, J.A.; Standaert, D.G.; Penney, J.B. Jr.; Young, A.B.; Landwehrmeyer, G.B. Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Brain Res. Mol. Brain Res. 1997, 48(2), 259-69.
103. Gainetdinov, R.R.; Mohn, A.R.; Bohn, L.M.; Caron, M.G. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc. Natl. Acad. Sci. USA 2001, 98(20), 11047-54.
104. Paterson, N.E.; Semenova, S.; Gasparini, F.; Markou, A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 2003, 167(3), 257-64
105. Schroeder, J.P.; Overstreet, D.H.; Hodge, C.W. The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats. Psychopharmacology (Berl) 2005, 179(1), 262-70.
106. Lee, B.; Platt, D.M.; Rowlett, J.K.; Adewale, A.S.; Spealman, R.D. Attenuation of behavioral effects of cocaine by the Metabotropic Glutamate Receptor 5 Antagonist 2-Methyl-6-(phenylethynyl)-pyridine in squirrel monkeys, comparison with dizocilpine. J. Pharmacol. Exp. Ther. 2005, 312, 1232-1240.
107. Warren, S.T.; Nelson, D.L. Advances in molecular analysis of fragile X syndrome. JAMA, 1994, 271, 536-542
108. Rudelli, R.D.; Brown, W.T.; Wisniewski, K.; Jenkins, E.C.; Laure-Kamionowska, M.; Connell, F.; Wisniewski, H.M. Adult fragile X syndrome, Clinico-neuropathologic findings. Acta Neuropathol. (Berl). 1985, 67, 289-295.
109. Hinton, V.J.; Brown, W.T.; Wisniewski, K.; Rudelli, R.D. Analysis of neocortex in three males with the fragile X syndrome. Am. J. Med. Genet. 1991, 41, 289-294.
110. Irwin, S.A.; Patel, B,; Idupulapati, M.; Harris, J.B.; Crisostomo, R.A.; Larsen, B.P.; Kooy, F.; Willems, P.J.; Cras, P.; Kozlowski, P.B.; Swain, R.A.; Weiler, I.J.; Greenough, W.T. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome, a quantitative examination. Am. J. Med. Genet. 2001, 98, 161-167.
111. Greenough, W.T.; Klintsova, A.Y.; Irwin, S.A.; Galvez, R.; Bates, K.E.; Weiler, I.J. Synaptic regulation of protein synthesis and the fragile X protein. Proc. Natl. Acad. Sci. USA 2001, 98, 7101-7106.
112. Huber, K.M.; Gallagher, S.M.; Warren, S.T.; Bear, M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation, Proc. Natl. Acad. Sci. USA 2002, 99, 7746-7750.
113. Musumeci, S.A.; Bosco, P.; Calabrese, G.; Bakker, C.; De Sarro, G.B.; Elia, M.; Ferri, R.; Oostra, B.A. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 2000, 41(1), 19-23.
114. Chen, L.; Toth, M. Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience, 2001, 103, 1043-50.
115. Berry-Kravis, E. Epilepsy in fragile X syndrome. Dev. Med. Child. Neurol. 2002, 44, 724-728.
116. Page, A.J.; Young, R.L.; Martin, C.M.; Umaerus, M.; O'Donnell, T.A.; Cooper, N.J.; Coldwell, J.R.; Hulander, M.; Mattsson, J.P.; Lehmann, A.; Blackshaw, L.A. Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons Gastroenterology 2005, 128, 402-10.
117. Hoang, C.J.; Hay, M. Expression of metabotropic glutamate receptors in nodose ganglia and the nucleus of the solitary tract. Am. J. Physiol. Heart. Circ. Physiol. 2001, 281, H457-462.
118. Lehmann, A.; Branden, L. Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog. Eur. J. Pharmacol. 2001, 431, 253-258.